DISCOUNT OPTIONSSCHEIN - AMGEN | Market Closed - Bid/Ask 12:49:20 2024-05-13 EDT | After market 14:10:16 | |||
| 1.06 EUR | -11.67% |
|
1.075 | +1.42% |
| Current month | +39.53% | ||
| 1 month | +14.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 1.06 | -11.67% | 0 |
| 24-05-10 | 1.2 | +5.26% | 0 |
| 24-05-09 | 1.14 | +9.62% | 0 |
| 24-05-08 | 1.04 | +5.05% | 0 |
| 24-05-07 | 0.99 | +3.13% | 0 |
Delayed Quote Börse Stuttgart
Last update May 13, 2024 at 12:49 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME22L0 |
| ISIN | DE000ME22L01 |
| Date issued | 2023-10-13 |
| Strike | 350 $ |
| Maturity | 2024-06-21 (39 Days) |
| Parity | 1 : 1 |
| Emission price | 2.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.67 € |
|---|---|
| Lowest since issue | 0.73 € |
| Spread | 0.1 € |
| Spread % | 8.77% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.2
USD
Average target price
314.6
USD
Spread / Average Target
+1.45%
- Stock Market
- Certificates
- Certificat
